Menu
Reference is made to the stock exchange announcement made by Nordic Nanovector ASA (now Thor Medical ASA, the "Company") on 3 July 2023 regarding grant of restricted share units ("RSU") to the members of the board.
The Company's board of directors has on 19 April 2024 resolved to issue 1,320,469 new shares in the Company towards the current members of the board pursuant to the RSU-program, of which 486,489 new shares have been issued to Ludvik Sandes, and 416,990 have been issued to each of John Andersen and Mimi Kristine Berdal.
Notifications of the transaction in accordance with the Market Abuse Regulation Article 19 are attached with this announcement.
This information is required to be disclosed under Section 5-12 of the Securities Trading Act.
Thor Medical is an emerging supplier of radionuclides, primarily alpha particle emitters, from naturally occurring thorium. Its proprietary production process requires no irradiation or use of nuclear reactors, and provides reliable, environmentally friendly, cost-efficient supply of alpha-emitters for the radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange under the ticker symbol ‘TRMED’.
To learn more, visit www.thormedical.no.
